Effective pain management plays a crucial role in the recovery process following lumbar spine surgery. Traditional methods often involve opioids, which can lead to unwanted side effects such as nausea, vomiting, and respiratory depression. However, a recent study has introduced a promising alternative: the combination of Erector Spinae Plane Block (ESPB) with nalbuphine. This innovative approach not only enhances pain relief but also reduces the need for opioid analgesics, promoting faster recovery.

Understanding Erector Spinae Plane Block (ESPB)

The posterior screw and rod fixation technique is widely used for lumbar trauma surgeries, but it often results in severe postoperative pain. Traditional pain relief strategies using opioids are limited by their side effects. Regional nerve block techniques, like ESPB, have gained prominence due to their effectiveness in reducing postoperative pain and minimizing opioid use.

First introduced by Forero et al. in 2016, ESPB injects local anesthetics into the fascial plane between the transverse process of the vertebral body and the erector spinae muscle. This block offers pain relief across the T₈~S₂ dermatomal levels, leveraging the interconnected fascial planes of the erector spinae muscle.

The addition of adjuvants to local anesthetics, such as opioids, has shown promise in extending their effects. However, their success has been limited. Nalbuphine, a mixed opioid receptor agonist-antagonist, offers a unique solution by providing pain relief while reducing adverse effects.

Role of Nalbuphine in Enhancing ESPB

Nalbuphine works by activating κ-receptors and antagonizing μ-receptors, providing pain relief with fewer side effects compared to opioids alone. Previous studies have demonstrated the analgesic benefits of nalbuphine in combination with other local anesthetics in spinal anesthesia and brachial plexus blocks. However, its effectiveness in enhancing ESPB with ropivacaine had not been explored until now.

A recent randomized, double-blinded, controlled trial investigated the use of nalbuphine as an adjuvant to ropivacaine in ESPB for patients undergoing lumbar trauma surgery. The results were promising, showing significant improvements in postoperative pain management.

Study Design and Methods

Conducted from July 2022 to September 2023 at the Second People’s Hospital of Wuhu, the study included 60 patients who met specific eligibility criteria. Patients were randomly assigned to two groups: one receiving 0.375% ropivacaine (Group R) and the other 0.375% ropivacaine combined with 10 mg nalbuphine (Group N) bilaterally via ESPB.

Anesthesia Administration

General anesthesia was induced using sufentanil, propofol, and rocuronium, followed by maintenance with propofol, remifentanil, sevoflurane, and intermittent rocuronium. The target bispectral index (BIS) was set between 40 to 60, and patients were monitored with standard equipment.

If blood pressure or heart rate increased by more than 20%, intravenous sufentanil was administered. Postoperatively, patients were given flurbiprofen axetil and ondansetron for pain and nausea management.

Erector Spinae Plane Block Procedure

ESPB was performed under ultrasonic guidance using a microconvex transducer. After skin preparation and identifying the L₂ lumbar transverse process and erector spinae muscle, local anesthetic or the combination of local anesthetic and nalbuphine was injected bilaterally.

Results

The study found that the time to first postoperative remedial analgesia was longer in Group N (489 ± 52 minutes) compared to Group R (391 ± 23 minutes). This difference suggests that the addition of nalbuphine significantly prolonged the duration of analgesia.

NRS scores at rest and during movement were lower in Group N at several postoperative intervals, indicating better pain management throughout the study period.

Moreover, Group N experienced reduced sufentanil consumption at several time points after surgery, highlighting the effectiveness of ESPB with nalbuphine in minimizing the need for opioid analgesics.

No significant differences were observed in postoperative complications, time to first off-bed, time to first flatus, length of hospital stay, or patient satisfaction between the two groups.

Discussion

The findings of this study add significant value to the field of regional anesthesia by demonstrating that the combination of ESPB and nalbuphine can effectively prolong pain relief and reduce the need for opioid analgesics. Post-surgical pain management is essential to facilitate rehabilitation and promote quicker recovery.

ESPB has been proven to be effective in reducing postoperative pain scores and minimizing opioid usage. The addition of nalbuphine to this technique enhances its analgesic effect and extends the duration of pain relief, making it an attractive option for post-lumbar surgery pain management.

The mechanism behind the improved analgesic efficacy of nalbuphine in combination with ropivacaine is multifaceted, involving partial μ-receptor antagonism, κ-receptor activation, and the inhibition of pain neurotransmitters. Further research is needed to elucidate the specific impact of nalbuphine on local anesthetic effects.

Conclusion

The use of nalbuphine as an adjuvant to ropivacaine in ESPB offers significant benefits for post-lumbar surgery pain management. This approach not only enhances pain relief and prolongs its duration but also reduces the reliance on opioid analgesics, improving patient safety and recovery outcomes.